| Literature DB >> 32723799 |
Maria I Rojas1,2, Giselle S Cavalcanti1,2, Katelyn McNair1,3, Sean Benler1,2, Amanda T Alker1,2, Ana G Cobián-Güemes1,2, Melissa Giluso1,3, Kyle Levi1,3, Forest Rohwer1,2,3, Barbara A Bailey4, Sinem Beyhan2,5, Robert A Edwards1,2,3, Nicholas J Shikuma6,2,3,5.
Abstract
Many commensal bacteria antagonize each other or their host by producing syringe-like secretion systems called contractile injection systems (CIS). Members of the Bacteroidales family have been shown to produce only one type of CIS-a contact-dependent type 6 secretion system that mediates bacterium-bacterium interactions. Here, we show that a second distinct cluster of genes from Bacteroidales bacteria from the human microbiome may encode yet-uncharacterized injection systems that we term Bacteroidales injection systems (BIS). We found that BIS genes are present in the gut microbiomes of 99% of individuals from the United States and Europe and that BIS genes are more prevalent in the gut microbiomes of healthy individuals than in those individuals suffering from inflammatory bowel disease. Gene clusters similar to that of the BIS mediate interactions between bacteria and diverse eukaryotes, like amoeba, insects, and tubeworms. Our findings highlight the ubiquity of the BIS gene cluster in the human gut and emphasize the relevance of the gut microbiome to the human host. These results warrant investigations into the structure and function of the BIS and how they might mediate interactions between Bacteroidales bacteria and the human host or microbiome.IMPORTANCE To engage with host cells, diverse pathogenic bacteria produce syringe-like structures called contractile injection systems (CIS). CIS are evolutionarily related to the contractile tails of bacteriophages and are specialized to puncture membranes, often delivering effectors to target cells. Although CIS are key for pathogens to cause disease, paradoxically, similar injection systems have been identified within healthy human microbiome bacteria. Here, we show that gene clusters encoding a predicted CIS, which we term Bacteroidales injection systems (BIS), are present in the microbiomes of nearly all adult humans tested from Western countries. BIS genes are enriched within human gut microbiomes and are expressed both in vitro and in vivo Further, a greater abundance of BIS genes is present within healthy gut microbiomes than in those humans with with inflammatory bowel disease (IBD). Our discovery provides a potentially distinct means by which our microbiome interacts with the human host or its microbiome.Entities:
Keywords: CIS; T6SS; bacteriophage; eCIS; microbiome; secretion system
Year: 2020 PMID: 32723799 PMCID: PMC7394362 DOI: 10.1128/mSystems.00648-20
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
FIG 1Bacteroidales possess a distinct contractile injection system gene cluster. (A) Contractile injection systems are related to the contractile tails of bacteriophages. There are two main types of CIS; type 6 secretion systems (T6SS) are bound to the bacterial cell membrane and act from within the producing cell, while extracellular CIS (eCIS) are released by bacterial cell lysis and bind to target cells. (B) Unrooted phylogeny of CIS sheath protein sequences. A BIS group with a known subtype 4 T6SS and eCIS (orange) are distinct from organisms with known subtype 1, subtype 2 and subtype 3 T6SS (Table S1). Bacteria with BIS identified in this study are highlighted in red. Bootstrap values are expressed in numbers of occurrences that support the phylogenetic structure out of 100, from 1,000 resampling events.
FIG 2BIS gene clusters are found in three genetic architectures. (A and B) Synteny plot of BIS gene clusters in Bacteroides and Parabacteroides species (A) compared to those of P. luteoviolacea MACs, S. entomophila Afp, Photorhabdus PVCs, and “Ca. Amoebophilus asiaticus” subtype 4 T6SS (B). Representative CIS gene cluster architectures are shown, with genes color coded according to function. Genes with no significant sequence similarity at the amino acid level to any characterized proteins are light gray. Sequence coordinates of all gene clusters are provided in Table S3.
FIG 3BIS genes are abundant in human gut and mouth microbiomes and present in other human microbiomes. (A) Coverage plot of BIS genes (log10 of 1,000,000 · hits/reads) in 8,320 microbiomes associated with mucosal tissue, i.e., gut, mouth, nose, and other (includes vaginal and skin) tissues from 232 healthy humans. (B) Ten BIS genes are often found together in human metagenomes (cooccurrence network). Node size represents the number of hits for each protein across all runs. Line weight represents the number of times that any two proteins occurred together within a data set.
FIG 4BIS genes are expressed in vivo in humanized mice. Coverage plot of BIS genes (normalized by number of reads and protein nucleotide size) from 59 stool metatranscriptomes of humanized mouse microbiomes.
FIG 5BIS genes are present in the microbiomes of a majority (99%) of adult individuals from the United States and Europe. Frequencies of 18 BIS proteins from fecal samples of 338 individuals are shown. (A) HMP (n = 214) from healthy North American individuals (8); (B) MetaHIT (n = 124) from a study of European individuals (30). Protein hits are normalized by individual donor.
FIG 6BIS genes are present in higher abundance in healthy individuals than in individuals with IBD. (A) Percentages of individuals possessing a given number of BIS proteins from 214 healthy, 103 IBD, and 28 prediabetes fecal microbiome samples; (B) percentages of individuals possessing a given relative abundance (percentage) of Bacteroidetes within their gut microbiomes.
Statistical analyses of BIS protein counts and Bacteroidetes abundance confidence intervals for the difference in frequency medians between healthy, prediabetes, and IBD groups by a percentile nonparametric bootstrap method
| Groups | BIS protein count (95% CI) | |
|---|---|---|
| Healthy vs IBD | 0.444* (0.349, 0.505) | 0.126* (0.058, 0.184) |
| Healthy vs prediabetes | 0.040 (–0.044, 0.163) | 0.218* (0.153, 0.302) |
| Prediabetes vs IBD | 0.404* (0.259, 0.484) | –0.092 (–0.186, –0.033) |
The estimated difference in medians and the corresponding 95th-percentile confidence intervals (95% CI) are reported. Confidence intervals that do not cover zero have significantly different medians, denoted with an asterisk. See Table S5 in the supplemental material for asymptotic Wilcoxon rank sum test results.